<DOC>
	<DOCNO>NCT01929486</DOCNO>
	<brief_summary>The purpose study investigate safety , pharmacokinetics , effect regulatory T cell depletion Mogamulizumab advance recurrent cancer patient .</brief_summary>
	<brief_title>Phase Ia/Ib Multicenter Trial Mogamulizumab Advanced Recurrent Cancer .</brief_title>
	<detailed_description>This study consist phase Ia Ib portion patient solid tumor . Phase Ia portion standard 3+3 dose-escalation design 0.1mg/kg , 0.5mg/kg 1.0mg/kg Mogamulizumab . Phase Ib portion randomize study compare 0.1mg/kg tolerate dose Mogamulizumab base phase Ia portion pursue safer immunologically efficient dose .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Patients histologically confirm , CCR4 negative lung , stomach , esophageal , ovarian skin cancer . 2 . Patients therapyresistant cancer . Patients recurrent cancer advance cancer refuse standard therapy . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 . 4 . Patients 20 year old time inform consent . 5 . No serious dysfunction major organ ( bone marrow , heart , lung , liver kidney ) meet following condition ; 1 ) WBC count : &gt; =1,500/mm3 2 ) Hemoglobin : &gt; =8.0g/dL 3 ) Platelet count : &gt; =75,000/mm3 4 ) Serum total bilirubin : &lt; =2.0 x ULN 5 ) AST ALT : &lt; =2.5 x ULN ( Patients hepatic infiltration attribute primary disease &lt; =5.0 x ULN ) 6 ) Serum creatinine : &lt; =1.5 mg/dL 7 ) SpO2 : &gt; =93 % 8 ) ECG : No abnormal finding . 9 ) EF : &gt; =50 % 6 . Agree use birth control include condom etc . time obtain first consent 24 week final administration study drug ( except female menopause ( 1 year last menstruation ) female/male operation sterilization ) . 7 . Given write informed consent . 8 . Patients hospitalize day first administration next day . 9 . Patients target lesion measurable RECIST ver.1.1 . 10 . Life expectancy &gt; = 3 month . 1 . Patients HIV antibody positive . 2 . Patients HCV antibody positive . 3 . Patients autoimmune disease . 4 . Patients HBs antigen HBVDNA positive . 5 . History serious anaphylaxis induce antibody preparation . 6 . Patients double cancer . 7 . Within 4 week treatment anticancer agent , immune suppressant , immune enhancer , cytokine therapy , radiotherapy surgery primary disease . 8 . Pregnant breastfeeding female females possibility pregnancy . 9 . Patients active infection . 10 . Patients psychosis dementia . 11 . Patients need continuous systemic administration adrenocorticosteroid . 12 . Patients receive hematopoietic stem cell transplantation . 13 . Patients presence suspicion CNS involvement . 14 . Patients administer investigational product within 4 week entry . 15 . Patients treat immunotherapy cancer ( e.g . cancer vaccine therapy ) within 12 week entry . 16 . Any inadequacy study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>